{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:51:05Z","timestamp":1790398265992,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cmi.2022.05.034","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T02:04:19Z","timestamp":1655085859000},"page":"1335-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression"],"prefix":"10.1016","volume":"28","author":[{"given":"David S.Y.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Lai M.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf L.","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.05.034_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1473-3099(07)70159-7","article-title":"Viral dynamics in transplant patients: implications for disease","volume":"7","author":"Funk","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00430-008-0082-5","article-title":"Dynamics of T cell memory in human cytomegalovirus infection","volume":"197","author":"Waller","year":"2008","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2022.05.034_bib5","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2022.05.034_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2022.05.034_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2022.05.034_bib9","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1007\/s15010-013-0504-1","article-title":"Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG\/\u00d6AG) (AWMF 055\/066)","volume":"41","author":"Thoden","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2022.05.034_bib10","first-page":"327","article-title":"Canadian consensus guidelines for the management of cytomegalovirus disease in HIV\/AIDS","volume":"15","author":"Lalonde","year":"2004","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00134-015-4205-3","article-title":"Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients","volume":"42","author":"Timmermans","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1473-3099(12)70197-4","article-title":"Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation","volume":"12","author":"Griffiths","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib14","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib16","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.05.034_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib21","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0140-6736(87)92560-8","article-title":"Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?","volume":"2","author":"Grundy","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.034_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.10.1.86","article-title":"Infections in solid-organ transplant recipients","volume":"10","author":"Patel","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2022.05.034_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbmt.2014.10.004","article-title":"Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease","volume":"21","author":"Bhutani","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.05.034_bib28","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0966-3274(99)80023-9","article-title":"Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms","volume":"7","author":"Borchers","year":"1999","journal-title":"Transplant Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.coi.2007.07.012","article-title":"Acceleration of allograft failure by cytomegalovirus","volume":"19","author":"Streblow","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation","volume":"340","author":"Lowance","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(94)92887-8","article-title":"Late-acute renal allograft rejection and symptomless cytomegalovirus infection","volume":"344","author":"Reinke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.034_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.100.1.61","article-title":"Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study","volume":"100","author":"Valantine","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2022.05.034_bib34","first-page":"CD003774","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2022.05.034_bib35","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.05.034_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archinte.158.9.957","article-title":"Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel","volume":"158","author":"Whitley","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/infdis\/166.6.1223","article-title":"Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group","volume":"166","author":"Gallant","year":"1992","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/379077","article-title":"Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome","volume":"37","author":"Kempen","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2022.05.034_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajo.2010.10.018","article-title":"Cytomegalovirus retinitis and the acquired immunodeficiency syndrome-bench to bedside: LXVII Edward Jackson memorial lecture","volume":"151","author":"Jabs","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cmi.2022.05.034_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ajcp\/93.5.651","article-title":"Cytomegaloviral adrenalitis and adrenal insufficiency in AIDS","volume":"93","author":"Pulakhandam","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cmi.2022.05.034_bib42","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(04)16500-8","article-title":"Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy","volume":"363","author":"Deayton","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.034_bib43","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jir060","article-title":"Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD41 T cell recovery on antiretroviral therapy","volume":"203","author":"Hunt","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(89)90312-7","article-title":"Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection","volume":"2","author":"Webster","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.034_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1378\/chest.127.1.233","article-title":"Cytomegalovirus infection in critically ill patients: associated factors and consequences","volume":"127","author":"Jaber","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2022.05.034_bib46","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1097\/CCM.0b013e31818f3fc4","article-title":"Increased mortality in long-term intensive care patients with active cytomegalovirus infection","volume":"36","author":"Ziemann","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jama.2008.697","article-title":"Cytomegalovirus reactivation in critically ill immunocompetent patients","volume":"300","author":"Limaye","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.05.034_bib48","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/jmv.21825","article-title":"Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit","volume":"82","author":"Chilet","year":"2010","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2022.05.034_bib49","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/cc10069","article-title":"Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis","volume":"15","author":"Heininger","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib50","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1097\/CCM.0b013e318260c90e","article-title":"Interferon-\u03b3 production by natural killer cells and cytomegalovirus in critically ill patients","volume":"40","author":"Chiche","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib51","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/jmv.23838","article-title":"Looking for biological factors to predict the risk of active cytomegalovirus infection in non-immunosuppressed critically ill patients","volume":"86","author":"Bravo","year":"2014","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2022.05.034_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcrc.2014.10.002","article-title":"Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers","volume":"30","author":"Frantzeskaki","year":"2015","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib53","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/CCM.0000000000000969","article-title":"Coreactivation of human herpesvirus 6 and cytomegalovirus is associated with worse clinical outcome in critically ill adults","volume":"43","author":"Roa","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/0310057X1604400514","article-title":"Cytomegalovirus infection in patients with sepsis due to bloodstream infections: lower risk and better outcomes in new versus already hospitalised intensive care unit admissions","volume":"44","author":"Osawa","year":"2016","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00134-015-4071-z","article-title":"Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome","volume":"42","author":"Ong","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib56","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/cix120","article-title":"Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock","volume":"64","author":"Ong","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib57","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1097\/CCM.0b013e31819ffea6","article-title":"Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients","volume":"37","author":"Chiche","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib58","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13613-019-0616-6","article-title":"Herpes simplex virus and cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO","volume":"9","author":"Hraiech","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib59","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1186\/s12879-021-06698-0","article-title":"Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib60","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.burns.2010.11.006","article-title":"Cytomegalovirus infection in severe burn patients monitoring by real-time polymerase chain reaction: a prospective study","volume":"37","author":"Bordes","year":"2011","journal-title":"Burns"},{"key":"10.1016\/j.cmi.2022.05.034_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051340","article-title":"Cytomegalovirus and herpes simplex virus effect on the prognosis of mechanically ventilated patients suspected to have ventilator-associated pneumonia","volume":"7","author":"Coisel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.05.034_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098819","article-title":"Reactivation of multiple viruses in patients with sepsis","volume":"9","author":"Walton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.05.034_bib63","article-title":"A\u00a0prospective monitoring study of cytomegalovirus infection in non-immunosuppressed critical heart surgery patients","volume":"10","author":"Roa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.05.034_bib64","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/520307","article-title":"High incidence of active cytomegalovirus infection among septic patients","volume":"26","author":"Kutza","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib65","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00003246-200103000-00012","article-title":"Human cytomegalovirus infections in nonimmunosuppressed critically ill patients","volume":"29","author":"Heininger","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib66","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3201\/eid1210.060411","article-title":"Active cytomegalovirus infection in patients with septic shock","volume":"12","author":"Von M\u00fcller","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib67","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/01.CCM.0000070222.11325.C4","article-title":"Occult herpes family viral infections are endemic in critically ill surgical patients","volume":"31","author":"Cook","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib68","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jama.2017.10569","article-title":"Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial","volume":"318","author":"Limaye","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.05.034_bib69","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jamainternmed.2017.0895","article-title":"Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial","volume":"177","author":"Cowley","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13613-020-00793-2","article-title":"Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation","volume":"11","author":"Papazian","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib71","article-title":"Reactivation of EBV and CMV in severe COVID-19\u2013epiphenomena or trigger of hyperinflammation in need of treatment? A large case series of critically ill patients","author":"Naendrup","year":"2021","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.idnow.2021.01.005","article-title":"High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19","volume":"51","author":"Simonnet","year":"2021","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.cmi.2022.05.034_bib73","first-page":"496","article-title":"Cytomegalovirus infection in critically ill patients with COVID-19","volume":"83","author":"Niitsu","year":"2021","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2022.05.034_bib74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.CCM.0000257325.88144.30","article-title":"A\u00a0contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients","volume":"35","author":"Papazian","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib75","doi-asserted-by":"crossref","first-page":"474.e1","DOI":"10.1016\/j.jcrc.2014.01.003","article-title":"Cytomegalovirus colitis in intensive care unit patients: difficulties in clinical diagnosis","volume":"29","author":"Chan","year":"2014","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2013.11.008","article-title":"Cytomegalovirus colitis in immunocompetent critically ill patients","volume":"20","author":"Siciliano","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5414\/CN108417","article-title":"Cytomegalovirus colitis in a critically ill, dialysis-dependent, acute kidney injury patient without immunosuppressive therapy","volume":"84","author":"Farah Musa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.cmi.2022.05.034_bib78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.CCM.0000201876.11059.05","article-title":"Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice","volume":"34","author":"Cook","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib79","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-018-2261-0","article-title":"Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort study","volume":"22","author":"van de Groep","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2022.05.034_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703256","article-title":"Cytomegalovirus in haematological tumours","volume":"12","author":"Alonso-\u00c1lvarez","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib81","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00277-014-2296-5","article-title":"Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine","volume":"94","author":"Chan","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2022.05.034_bib82","first-page":"CD008078","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","volume":"2012","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2022.05.034_bib83","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2022.05.034_bib84","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.034_bib85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/tid.12162","article-title":"High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network","volume":"16","author":"Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4081\/reumatismo.2016.897","article-title":"Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter?","volume":"68","author":"Mencarini","year":"2016","journal-title":"Reumatismo"},{"key":"10.1016\/j.cmi.2022.05.034_bib87","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1097\/MIB.0000000000000489","article-title":"Antiviral therapy in steroid-refractory ulcerative colitis with cytomegalovirus: systematic review and meta-analysis","volume":"21","author":"Shukla","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib88","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MCG.0000000000000758","article-title":"Corticosteroids and thiopurines, but not tumor necrosis factor antagonists, are associated with cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis","volume":"51","author":"Shukla","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cmi.2022.05.034_bib89","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10096-014-2212-x","article-title":"CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis","volume":"34","author":"Goodman","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib91","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.55563\/clinexprheumatol\/pqa98i","article-title":"Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases","volume":"39","author":"Ota","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cmi.2022.05.034_bib92","doi-asserted-by":"crossref","first-page":"ofz445","DOI":"10.1093\/ofid\/ofz445","article-title":"Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens","volume":"6","author":"Zappulo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ajh.26094","article-title":"Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution","volume":"96","author":"Leserer","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2022.05.034_bib95","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2022.05.034_bib96","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/infdis\/jix048","article-title":"Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia","volume":"215","author":"Boeckh","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib97","first-page":"393","article-title":"Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: implications for the diagnosis of CMV pneumonia","volume":"78","author":"Pi\u00f1ana","year":"2019","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2022.05.034_bib98","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1128\/JCM.42.5.2168-2172.2004","article-title":"Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry","volume":"42","author":"Chemaly","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.05.034_bib99","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-6143.2005.00747.x","article-title":"Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients","volume":"5","author":"Chemaly","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2022.05.034_bib100","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/655472","article-title":"Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature","volume":"202","author":"Van De Berg","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.034_bib101","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bmt.1702562","article-title":"Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited","volume":"26","author":"Barry","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.05.034_bib102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41590-018-0082-6","article-title":"Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells article","volume":"19","author":"Hammer","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cmi.2022.05.034_bib104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2022.05.034_bib105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00134-015-4066-9","article-title":"Cytomegalovirus reactivation in ICU patients","volume":"42","author":"Papazian","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.05.034_bib106","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u2019indirect\u2019 effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200310X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200310X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:49Z","timestamp":1761118309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2200310X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1198743X2200310X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.034","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}